Sanofi expanded the sales reach of the drug with approvals in the lucrative chronic obstructive pulmonary disease (COPD) ...

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it raised its sales growth ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was ...

The pharmaceutical company’s top line grew faster than analysts expected for the second quarter due to drug launches and ...

In the first quarter of 2024, Dupixent generated global product sales of $3.09 billion (€2.84 billion), which were recorded by Sanofi, representing growth of 24.9% at a constant exchange rate.

Dupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in smokers. It’s the sixth FDA ...

Dupixent is a key top-line driver for Sanofi and Regeneron. During first-half 2024, Sanofi recorded €6.14 billion from Dupixent product sales, indicating 27% year-over-year growth.